Literature DB >> 11733706

Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats.

Z de Saint Hilaire1, M Orosco, C Rouch, G Blanc, S Nicolaidis.   

Abstract

The role of brain amines in mediating the effects of the wake-promoting agent modafinil, used in the treatment of sleepiness associated with narcolepsy is still uncertain. Therefore we studied the effects of modafinil on extracellular serotonin (5-HT), dopamine (DA) and noradrenaline (NA), in rat prefrontal cortex and in the medial hypothalamus area. Modafinil (128 mg/kg i.p.) significantly increased waking in the first 4 h of EEG sleep recording. This cortical and behavioral activation was associated with an initial increase in extracellular 5-HT, DA and NA during the first 60 min following modafinil administration. In the prefrontal cortex, 5-HT release remained high for 3 h after modafinil administration. In contrast, in the hypothalamus, only NA release was enhanced while DA and 5-HT levels remained low. In a first step, modafinil may generate waking partly via cortical monoamine release, particularly DA and 5-HT, and also hypothalamic NA. In a second step, maintenance of waking might depend on hypothalamic NA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11733706     DOI: 10.1097/00001756-200111160-00032

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  45 in total

Review 1.  Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.

Authors:  Selene R T Veerman; Peter F J Schulte; Lieuwe de Haan
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

2.  Essential role of dopamine D2 receptor in the maintenance of wakefulness, but not in homeostatic regulation of sleep, in mice.

Authors:  Wei-Min Qu; Xin-Hong Xu; Ming-Ming Yan; Yi-Qun Wang; Yoshihiro Urade; Zhi-Li Huang
Journal:  J Neurosci       Date:  2010-03-24       Impact factor: 6.167

3.  Receptor-Based Discovery of a Plasmalemmal Monoamine Transporter Inhibitor via High Throughput Docking and Pharmacophore Modeling.

Authors:  Martín Indarte; Yi Liu; Jeffry D Madura; Christopher K Surratt
Journal:  ACS Chem Neurosci       Date:  2010-03-17       Impact factor: 4.418

4.  Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents.

Authors:  Neil E Paterson; Allison Fedolak; Berend Olivier; Taleen Hanania; Afshin Ghavami; Barbara Caldarone
Journal:  Pharmacol Biochem Behav       Date:  2010-03-25       Impact factor: 3.533

5.  Modafinil Activates Phasic Dopamine Signaling in Dorsal and Ventral Striata.

Authors:  Martin J Bobak; Matthew W Weber; Melissa A Doellman; Douglas R Schuweiler; Jeana M Athens; Steven A Juliano; Paul A Garris
Journal:  J Pharmacol Exp Ther       Date:  2016-10-12       Impact factor: 4.030

6.  A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia.

Authors:  Mohammad Arbabi; Mohaddeseh Bagheri; Farzin Rezaei; Seyyed-Ali Ahmadi-Abhari; Mina Tabrizi; Farahnaz Khalighi-Sigaroudi; Shahin Akhondzadeh
Journal:  Psychopharmacology (Berl)       Date:  2011-09-24       Impact factor: 4.530

Review 7.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

8.  Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications.

Authors:  Nora D Volkow; Joanna S Fowler; Jean Logan; David Alexoff; Wei Zhu; Frank Telang; Gene-Jack Wang; Millard Jayne; Jacob M Hooker; Christopher Wong; Barbara Hubbard; Pauline Carter; Donald Warner; Payton King; Colleen Shea; Youwen Xu; Lisa Muench; Karen Apelskog-Torres
Journal:  JAMA       Date:  2009-03-18       Impact factor: 56.272

9.  Behavioral responses of dopamine beta-hydroxylase knockout mice to modafinil suggest a dual noradrenergic-dopaminergic mechanism of action.

Authors:  Heather A Mitchell; James W Bogenpohl; L Cameron Liles; Michael P Epstein; Donna Bozyczko-Coyne; Michael Williams; David Weinshenker
Journal:  Pharmacol Biochem Behav       Date:  2008-07-25       Impact factor: 3.533

10.  Modafinil in the treatment of excessive sleepiness.

Authors:  Jonathan R L Schwartz
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.